Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

Clinical Pharmacology & Therapeutic uses of Diuretic Agents: A Review

Mayankesh Pandey[1], Akanksha Singh[2], Namrata[2], Nidhee Agnihotri[3], Roshan Kumar[4], Purabi Saha[5], Ravi Pratap Pandey[6], Amit Kumar[2] and Shiwangi[7]

[1]Principal, Vidya Bhavan College of Pharmacy, Rautapur, Chaubeypur, Kanpur Uttar Pradesh, INDIA.

[2]Research Scholar, Department of Pharmacy, Advance Institute of Biotech and Paramedical Sciences, Kanpur, Uttar Pradesh, INDIA.

[3]Assistant Professor, Department of Pharmaceutical Chemistry, Maharana Pratap College of Pharmaceutical Sciences, Kanpur Uttar, Pradesh, INDIA.

[4]Research Scholar, Department of Pharmacology, Dev Bhoomi Institute of Pharmacy and Research, Dehradun, Uttarakhand, INDIA.

[5]Department of Pharmacy, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun-248007, Uttarakhand, INDIA.

[6]Assistant Professor, Department of Pharmacology, Advance Institute of Biotech and Paramedical Sciences, Kanpur Uttar Pradesh, INDIA.

[7]Research Scholar, Dept. of Pharmaceutics, Shri Ramnath Singh Institute of Pharmaceutical Science and Technology, Sitholi, Gwalior, INDIA.

[1]Corresponding Author: mayankeshp505@gmail.com

www.jrasb.com || Vol. 1 No. 3 (2022): August Issue

Received: 27-07-2022	**Revised:** 18-07-2022	**Accepted:** 28-07-2022

ABSTRACT

The osmolarity of both blood and urine will increase if the kidneys are unable to eliminate excess water and electrolytes. NPS can be treated by restricting salt intake and using diuretics. Loop diuretics. Salt and water are flushed out of the body by diuretics. Medications have a sodium-lowering effect. arteries parched with salt BP-lowering. Albumin and diuretics both have the effect of decreasing sensitivity. Furosemide inhibits albumin. Fail-safe. Albuminuria, coagulopathy, dyslipidemia, edema. Diuretics are used to treat both edema and non-edema. Diuretics are used to treat heart failure, high blood pressure, and ascites (and other disorders when applicable). Treatment of heart failure, side effects, off-label usage, dose, pharmacokinetics, monitoring, and interactions are all topics that will be covered in this article. Thiazide diuretics that are authorized by the FDA impede between 3 and 5 percent of nephron DCT sodium reabsorption. Thiazides cause a person to urinate more often. Nephron trafficking is slowed down when diuretics are used. Furosemide, bumetanide, torsemide inhibit Na-K-2Cl (SLC12A1). Chloride-binding proteins can only be bound to by anions. Perform the initial dose once again. Bronchodilators that open up the airways. The administrator of the test will be able to tell if your airways constrict (spirometry). Chemicals that because inflammation weaken smooth muscle. Drops of 15 percent in the forced expiratory volume in one second (FEV1) suggest airway hyperreactivity and inflammation.

Keywords- Diuretics, inhibitor, Hypercalcemia, Heart failure, Pharmacokinetics dosing.

I. INTRODUCTION

Nephrotic syndrome, liver cirrhosis, and heart failure are all conditions that can be treated with diuretics. Edoema accumulates connective tissue fluid. Disease affects fluid composition. It is necessary to treat the underlying cause of edoema, which may include issues with the kidneys or the heart. Hypertension, renal failure, diabetes insipidus, hypercalcemia, and calcium loss are among conditions that can be helped with

Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

diuretics. [1] In order to bring down blood pressure, the kidneys get rid of salt and water, which in turn reduces plasma volume and the "pushing" on the artery walls. Diuretics are medications that get rid of excess water, salt, poisons, and waste. The osmolarity of both blood and urine will increase if the kidneys are unable to eliminate excess water and electrolytes. Diuretics and a reduction in salt intake are the standard treatments for NPS. Loop diuretics are what you should take. Salt and water are flushed out of the body by diuretics. Medications deplete sodium. Salt dehydrates arteries. decrease of blood pressure (BP) The transfer of albumin and diuretics both have a sensitising effect. Albumin inhibits furosemide. Fail- safe. Albuminuria, coagulopathy, dyslipidemia, edoema decreased. Diuretics are effective in treating non-and edoema. Diuretics Heart failure, hypertension, and ascites can all be treated with diuretics (and other disorders when applicable). Take into consideration therapy for heart failure, trends of adverse events, off-label applications, appropriate dosage, pharmacokinetics, monitoring, and interactions [2,3]. (Such as off-label uses and dose, as well as pharmacodynamics and pharmacokinetics, monitoring, and relevant interactions).

Water, which makes up more than 60 percent of an adult's weight, serves several functions in the body. electrolytes and fluids that are good for you. Natriuretic peptides govern fluid equilibrium. Urine removes both water and electrolytes from the body. Electrolytes stabilise urine. Electrolytes have an effect on the overall water balance.

Diuretics decrease electrolytes. Urinate. Tubule pH is increased when Na+ reabsorption is decreased. Tubular hyperosmolarity is caused by osmotic diuretics, however this effect is not felt in the body's electrolyte balance. [4,5]

Mechanism of Action

Diuretics are known to block nephronal transport (Figure 1A). Furosemide, bumetanide, and torsemide inhibit Na-K-2Cl (SLC12A1). [6] Anions bind to the region on transport proteins that is responsible for chloride binding (Fig 1B, see below for clinical relevance). [Transporter inhibitors have a size comparable to chloride. Thiazides are able to bind to the DCT sodium chloride cotransporter (SLC12A3). Diuretics are bound to the thiazide-sensitive NCC (Fig 1A). Loop and DCT diuretics are luminal.



Fig1 (a) & (b) Diuretic and salt-reabsorption sites in nephrons. nephron segment salt reabsorption percentages (A). (B) Extracellular picture of NKCC2's homology model. The arrow points to the ion-transporting and diuretic-binding compartment. A phenylalanine mutation (F372) affects diuretic binding. CAIs, DCTDs, loop diuretics, and MRs all refer to aldosterone.

II. CARBONIC ANHYDROUS INHIBITORS

CAIs are used to treat conditions such as altitude sickness, heart failure, and epilepsy. CAIs are diuretics. Glaucoma and cerebral hypertension can both be treated with CAIs. Glaucoma, IIH, and associated disorders require careful treatment. The following topics are discussed: off-label usage; dosage; pharmacodynamics; and pharmacokinetics. [7]

Mechanism of Action



Fig: 2 Diuretics which inhibit carbonic anhydrase.

Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

Administration

There are a variety of delivery methods for CAIs. Carbonic inhibitors include acetazolamide, methazolamide, dorzolamide, brinzolamide, diclofenamide, ethoxzolamide, and zonisamide. Glaucoma inhibitors can be applied topically or taken orally through the body. [7,8] Dorzolamide and brinzolamide are able to make their way through the cornea and into the ciliary body. These medications for glaucoma can be used on their own, but more commonly they are combined with others. When used alone, one drop of dorzolamide hydrochloride or brinzolamide should be placed in each eye three times per day. When combined with other glaucoma medications, the recommended dosage is two drops twice day. 2 percent/0.5 percent timolol/dorzolamide solution is also available. When topical medication fails to lower intraocular pressure and vomiting is expected in patients with acute angle-closure glaucoma, systemic carbonic inhibitors are an effective treatment option. [Citation needed] [Citation needed] [9] Oral 125, 200, and 500 mg acetazolamide tablets are available. Patients diagnosed with glaucoma may require 250-1000 mg each day. Altitude disease demands larger dosages. Carbonic anhydrase inhibitors are employed in the treatment of edoema, epilepsy, and the diuresis associated with congestive heart failure. [10] After intravenous injection, the benefits may be seen in their entirety as soon as 20 minutes later. In its present state, methazolamide may be obtained in liquid form. When treating glaucoma, a dosage of 50 to 100 mg twice day or three times daily is recommended, whereas altitude sickness is treated with 150 to 200 mg taken once daily. Treatment for open-angle and preoperative acute closed-angle glaucoma is available in the form of oral dichlorphenamide tablets of 50 mg. Patients who are using carbonic anhydrase inhibitors are strongly encouraged to drink enough of water right away in order to avoid developing kidney stones.

Loop Diuretics

The conditions of heart failure, cirrhosis, nephrotic syndrome, and hypertension can all be treated with loop diuretics. Fluid overload and high blood pressure can be treated with loop diuretics. Taking a look at the indications, actions, and potential side effects. The members of the interprofessional team will educate themselves on the adverse event profile and the mechanism of action of the medicine. [11]

Mechanism of Action



Fig. 3: The right upper limb of the loop of Henle expresses a Na/K/2Cl cotransporter that is sensitive to furosemide.

Administration

Loop diuretics are available in IV and oral formulations.

The dosages of furosemide that are available in tablet form are 20 mg, 40 mg, and 80 mg. An injectable solution has 10 milligrammes of the active component contained inside one millilitre of the solution. Both 8 mg/mL and 10 mg/mL concentrations are offered for use in oral solutions. Patients should begin treatment with a beginning dose of 5 mg when taking the tablet form of the medication. At a concentration of ten milligrammes per millilitre of injection fluid. Oral bumetanide is available in tablet form with a dosage of 0.5, 1, and 2 milligrammes. [12] In terms of concentration, the intravenous solution has a value of 0.25 milligrammes per millilitre.

There is a tablet form of ethacrynic acid available (25 mg), as well as a powder form (50 mg) for intravenous administration. The bioavailability of each of the loop diuretics is distinct from one another. The bioavailability of bumetanide and torsemide is much closer to 80 percent than that of furosemide, which has a bioavailability of about 50 percent on average.

Fluorosimide has a half-life that ranges from 1.5 to 2 hours; however, patients who suffer from renal/hepatic dysfunction or heart failure might

Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

experience a half-life that is up to 2.6 hours. [13] Patients who suffer from renal/hepatic dysfunction or heart failure have a prolonged half-life, which can vary from 1.3 to 1.6 hours. This is because their organs are not functioning properly. Torsemide's half-life, which is the longest of the three or four medications, can be as long as five or six hours in patients who have kidney/hepatic dysfunction or heart failure. Torsemide's half-life is the longest of the three or four drugs. The beginning of the action in each of the three loops is, in most respects, identical. Oral administration typically takes between 30 and 60 minutes for all three of these drugs. [6,2] Patients who have heart failure or hepatic dysfunction may benefit even more from the diuretic effects of torsemide, which has the longest duration of action out of all the available medications.

III. THIAZIDE

Thiazide diuretics are able to block between three and five percent of the luminal sodium reabsorption that occurs in the distal convoluted tubule of the nephron. Natriuresis and diuresis are both facilitated by thiazide diuretics. HCTZ, chlorthalidone, and indapamide are the thiazide diuretics that are recommended to patients the most frequently. [14] Both HCTZ and chlorthalidone are viable treatment options for primary hypertension. Chf, cirrhosis, corticosteroids, and oestrogen therapy can all cause edoema, which can be treated with HCTZ and chlorthalidone. [15,16] It has been given FDA approval for treating CHF-related salt and fluid retention as well as primary hypertension, either on its own or in combination with other medications. This activity provides a description of thiazide diuretics in order to assist medical professionals in directing patient therapy based on indications, mechanisms of action, administration methods, severe side effects, contraindications, toxicity, and monitoring.

Mechanism of Action



Fig. 4: Thiazide diuretics compete for the Na/Cl cotransporter's chloride binding site, reducing its ability to transport ions.

Administration

Thiazide is an ingredient found in diuretics. Supplements for breakfast. Guidelines for administering HCTZ with chlorthalidone in different amounts. Both antihypertensive medications can have their dosage raised to either 50 or 100 milligrammes. Patient requirements should influence dosing. Fluid accumulation and edoema: between 50 and 100 mg. [5,6,7]

Potassium Sparing Diuretics

Diuretics that spare potassium are helpful in keeping potassium levels stable. 19 Studies have shown that thiazide and thiazide-like diuretics can lead to ventricular ectopy and sudden death. On the other hand, potassium-sparing diuretics are able to circumvent this risk. 19 SPIR, EPLER, amiloride, and triamterene decrease CVEs. SPIR, amiloride, and HCTZ all contribute to a reduction in resistant hypertension. [13–16]

Mechanism of action



Fig. 5: Cortical collecting duct K-sparing diuretics. These nephron cells absorb Na through epithelial luminal Na channels (ENaC). Na influx across the luminal membrane leaves lumen-negative potential, driving Cl reabsorption and potassium outflow.

Osmotic Diuretic

Diuretics induce urination. Diuretics are medications that are taken to rid the body of excess water, salts, and urea. They extract the toxic fluid from the tissue (edoema). [20,21] To prevent fluid from being reabsorbed into the circulation from the renal tubules, diuretics are used. The reabsorption of salt and water by the kidneys is inhibited by benzothiadiazides like chlorothiazide. Both salt and water stimulate the generation of urine. In the 1950s, benzothiadiazides came to replace the majority of diuretics. Because they are tablets, they are really handy. Hypertension can be lowered by taking medication. [22]

Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

Mechanism of Action



Fig. 6: Mannitol, a sugar alcohol that doesn't pass cell membranes, inhibits salt and water reabsorption in the proximal tubule and loop of Henle. Sodium loses more water than potassium.

Administration

In plasma, acetazolamide is protein-bound at a concentration of 93%. 1 to 1.5 hours after oral administration, with oral bioavailability of 95%. thrice daily with a half-life of 13 hours In patients with renal insufficiency, tubular secretion is responsible for the elimination of ninety percent of the drug. Mannitol that is ingested orally is not absorbed at all once it is given intravenously. Both the viscosity and the hematocrit of the blood are decreased by mannitol. The filtration process for mannitol is quite rapid, and it then turns to glycogen. After 70 to 150 minutes, more than 90 percent is removed through the urine.

Indication

Water accounts for around sixty percent of an adult's total body weight and is essential to a variety of physical functions. An electrolyte and fluid imbalance can be dangerous; hence it is essential to maintain a healthy fluid and electrolyte balance. The neuronal regulation of thirst, hormonal regulation (vasopressin and Natriuretic Peptides),[23] management of the skin, variations in hemodynamic activity, and renal control of salt and water excretion all contribute to the maintenance of fluid balance. The elimination of waste products of metabolism, excess electrolytes, and water through the urine is a function of the kidneys. Electrolyte balancing is connected to both the intracellular environment (which contains a lot of K+ ions) and the extracellular environment (which contains a lot of Na+ and Cl- ions). Fluid volume can be altered by medications that have an effect on the renal excretion of electrolytes. [24,25]

Pharmacokinetics of diuretics

The metabolism of loop diuretics is shown in figure 7. Within half an hour to two hours after intravenous administration, furosemide, bumetanide, and torsemide reach their maximum concentrations. The oral bioavailability of bumetanide and torsemide is around 80 percent, but the oral bioavailability of furosemide is just 50 percent. [25,57]. Even though furosemide has a relatively fast t1/2, it is possible that its oral absorption is slower than its elimination time, which would result in a longer duration of action. It's possible that "absorption-limited kinetics" [23,56] can explain what we call a "six-hour memory" [24,26]. Orally administered bumetanide and torsemide are rapidly absorbed [27]. When a patient is moved from an intravenous to an oral loop diuretic, the dose of bumetanide or torasemide should be kept at the same level, but the dose of furosemide should be increased [55,27]. Due to the fact that other variables influence the effectiveness of diuretics, it is impossible to develop a set intravenous/oral conversion [28]. Tablets that are taken orally might be difficult to deliver for certain owners, which can result in noncompliance with treatment, particularly when the treatment is ongoing. It might be challenging to provide tablets or capsules to a cat.

It has been determined whether or not many alternative approaches and formulations are effective. Because of this research, the sublingual tablet form of sildenafil citrate for the treatment of pulmonary arterial hypertension, nitroglycerin ointment for the treatment of congestive heart failure, the transdermal patch form of tulobuterol for the treatment of bronchodilation, and the transdermal patch form of bisoprolol for the treatment of postoperative atrial fibrillation were developed. There are advantages to using ODFs, particularly for children. It is simple to swallow, it dissolves quickly, and there is little risk of choking [23,55]. ODFs that are not invasive are used in the field of veterinary medicine. It is possible that the sublingual route offers therapeutic benefits over the oral route, particularly for individuals suffering from CHF. Furosemide's diuretic effects in dogs have been studied in veterinary medicine [28,43] utilising IV, SC, PO, and CRI administration routes.



Fig. 7: ADME Comparing oral vs. IV diuretic plasma levels. Normal and edematous natriuretic thresholds are shown by dashes. Time over the threshold determines natriuresis, hence route of administration

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

affects stable and severely edematous individuals differently. A typical person may benefit from an oral dose notwithstanding bioavailability. Classic dose-response vs plasma logarithm.

The usage of sublingual furosemide was found to produce buccal mucoadhesion and permeability of the tongue [28]. It was determined that administration through the cat's skin was ineffective [29,52,53]. Uncharted territory for the dog. ODFs are not present in cats and small dogs. T1/2 diuretics (see table 1). One dosage is equivalent to 16–21 hours of salt and water replacement. The retention of NaCl postdiuretic results in a decreased excretion. Dosage next [54]. Even in the absence of diuretic treatment, individuals with decompensated edoema may have a positive NaCl balance and a low urine NaCl concentration. Successful loss of sodium chloride. Natriuresis and antinatriuresis are both produced by diuretics. Torsemide is not sufficient for bumetanide treatment. CKD causes furosemide's t1/2 to prolong, which increases the drug's effectiveness in comparison to bumetanide. The effectiveness of treatment administered twice day is decreased when the duration of the internatriuretic is long. An excessive amount of NaCl in the diet leads to NaCl retention in the kidneys and a positive NaCl balance. Patients with t1/2 may benefit from using loop diuretics. Injections are recommended, according to recent recommendations [31,]. After only one dosage, the long-acting form of torsemide more than doubled the amount of salt and water lost while having no effect on the amount of potassium excreted [32,51]. It is possible that therapy might be improved by avoiding short-acting loop diuretic pharmacokinetic restrictions.

Table: 1 Pharmacokinetics of commonly used Diuretics

Diuretic	Oral Bioavailability %	Elimination t1/2 h			
		Normal	CKD	CirrhoticAscites	Heart Failure
Furosemide	50(10-100)	1.5-2	2.8	2.5	2.7
Bumetanide	80-100	1	1.6	2.3	1.3
Toresemide	65-100	3-4	4-5	8	6
Hydrochlorothiazide	55-77	6-15	Prolonged		
Metolazone	70-90a	14-20	Prolonged		
Amiloride	~50b	6-26	100		
Sprionolactone	90	1.5c	d		

Diuretics in Diagnosis

Furosemide/ Fludrocortisone test: This disorder is characterised by low urine acidification capacity (dRTA) without metabolic acidosis. Wrong and Davies (1959) reported three people who couldn't acidify their urine after an oral acid load (100 mg [1.86 mmol] ammonium chloride/kg body wt). [31,50]. This study established the "gold standard" one-day "short" ammonium chloride loading test [31,49]. Many definitions of dRTA have been employed, includinga pH of 5.3 as a threshold, but there has never been a clear consensus (2–8). Using non-uniform definitions and provocative assays, partial dRTA in recurrent stone-formers ranged from 2% to 21%. (3,9,10). Stone clinics rarely perform urine acidification tests, although they collect routine clinical data on nephrolithiasis patients. Conventional nonprovocative clinical criteria don't accurately predict incomplete dRTA, and earlier recommendations were based primarily on expert opinion (10,11). Even though the ammonium chloride loading test can be performed in some places, gastrointestinal adverse effects are common after ingestion. Walsh et al. described the furosemide/fludrocortisone test in 2007 [47,48]. Viljoen et al. showed that the furosemide/fludrocortisone test had a greater false positive rate of incomplete dRTA diagnosis in ten nephrolithiasis or nephrocalcinosis patients (all without dRTA). Fludrocortisone wasn't given simultaneously, but 10 hours before the test [33,34,46]. No solid data supports the use of a furosemide/fludrocortisone test in stone-forming patients.

Mannitol Challenge Test: Challenge tests measure lung function after inhaling toxins. A Mannitol challenge test may be used to diagnose exercise-induced asthma or evaluate asthma medication. Asthma tightens airways. During the MCT, you gradually inhale Mannitol.

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

IV. ENHANCING HEALTHCARE TEAM OUTCOMES

If the initial dose does not have any effect, you will be given further ones. Bronchodilators that are inhaled widen the airways. The administrator of the test will know whether or not your airways constrict before you do (spirometry). Chemicals that promote inflammation produced by inflamed cells cause smooth muscle to contract. Decreases of 15 percent in the forced expiratory volume in one second (FEV1) indicate airway hyperresponsiveness and inflammation. MCT is asthmatic-specific as well as sensitive. MCT is more particular than histamine and methacholine, which are less specific. Clinicians, specialists, NPs/PAs, nurses, and pharmacists deliver diuretics. It is necessary to have an understanding of the diuretic's adverse effects, as well as your diet and lifestyle. Patients who are considered outpatients are required to report compliance and adverse effects. The effectiveness of diuretics increases when patients stick to their treatment plans and take their medications as directed. Vericiguat (MK-1242) for the treatment of patients with heart failure and a low ejection fraction. [35,45] Those with an NTproBNP level of 8000 pg/ml at the age of 75 reacted better to Vericiguat. Benazepril should be prescribed by clinicians, nurse practitioners (NPs), pharmacists, and nurses. The dose, interactions, and potential side effects of medications are all evaluated by pharmacists. Nurses are responsible for carefully monitoring patients' blood pressure and dispensing prescriptions. Benazepril must be administered by a multidisciplinary group of healthcare professionals in order to get the best possible therapeutic results and prevent unfavourable reactions to medicine. It is important to be vigilant while dealing with carbonic anhydrase inhibitors, hepatic failure, and SJS/TEN. It is essential for clinicians, nurses, and pharmacists to be aware of the potential adverse effects of these drugs. Communication between the healthcare team and the patient helps to minimise risks. [36,38,44] When using carbonic anhydrase inhibitors, patients with poor kidney and liver function need to be watched closely. Nurses provide assistance to both medical professionals and patients. The evaluation of drug-drug interactions and patient education on dosage, route of administration, and potential adverse effects are the responsibilities of pharmacists. CAI symptoms are alleviated by interprofessional treatment. The administration of mannitol has to involve several disciplines. Alterations in fluid levels can lead to heart failure. Keeping an eye on the levels of sodium, potassium, and osmolality. Immediately notify your supervisor if the lab findings are abnormal. Stop taking mannitol if your electrolyte or osmolality levels are already at a healthy level. When treating cerebral edoema with mannitol, it is important to check the osmolality of the serum every 4-6 hours. A hypertonic solution is required for levels higher than 320 MOs. Abnormalities in urine production have to be reported to the physicians by nurses. The pharmacist analyses the dosages and makes suggestions on possible drug interactions. In the event that mannitol is ineffective, the physician may recommend an alternative treatment. Any treatment, including mannitol, can be improved by improving communication. [39,42,43]

In the event that a patient's condition deteriorates, nurses are required to notify the patient's attending physician. ICUs protect patients by maintaining up-to-date charts of urine output, assessing body weight on a regular basis, and doing arterial blood gas analysis. Outpatient pharmacists evaluate the interactions between medications and the appropriate doses. Requests for diuretics that are available over-the-counter ought to be turned down and reported. Interprofessional teams that may include cardiologists, otolaryngologists, clinical pharmacists, and nurses' work together to reduce the adverse effects of diuretics. [40,41,42]

V. CONCLUSION

Fluid retention and hypertension are both reduced with loop diuretics. The staff should be aware of the uses, side effects, and potential dangers of the medication. When choosing a diuretic and the appropriate dose, exercise extreme caution. When prescribing loop diuretics, clinicians, pharmacists, and nurses need to collaborate in order to lessen the likelihood of side effects. Using eye drop bottles that have tips of varying colours helps prevent overdose. Numerous randomized-control studies and meta-analyses have proven that topical carbonic anhydrase inhibitors, such dorzolamide and brinzolamide, are both safe and effective in treating a variety of conditions. Thiazide diuretics are a safe treatment option for hypertension and heart failure. These medications are effective in treating chronic edoema. Hypokalemia is most frequent. Arrhythmias are a rare side effect of thiazide. Only five percent of the population suffers from resistant hypertension, a condition that can lead to illness and even death. Potassium-preserving diuretics are not being used to their full potential.

DECLARATIONS

Conflict of Interest- No potential conflicts of interest are declared by the authors.

Ethical Approval- This article does not contain any experiments involving human subjects or animals that were conducted by the author.

REFERENCES

[1] Dubey, A., Ghosh, N. S., Rathor, V. P. S., Patel, S., Patel, B., &Purohit, D. (2022).Sars- COV-2 infection leads to neurodegenerative or neuropsychiatric diseases.

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

International Journal of Health Sciences, 6(S3), 2184–2197. https://doi.org/10.53730/ijhs.v6nS3.5980.

[2] Saha, P., Nyarko, R. O., Lokare, P., Kahwa, I., Boateng, P. O., & Asum, C. (2022). Impact of Covid-19 in Management of Lung Cancer Disease: A Review. Asian Journal of Pharmaceutical Research and Development, 10(3), 58-64.

[3] Anubhav Dubey, Yatendra Singh. Medicinal Properties of Cinchona Alkaloids - A Brief Review. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(3):224-8. doi: 10.52711/2231-5659.2021.00036

[4] Yadav, K., Sachan, A., Kumar, S., & Dubey, A. (2022). Techniques For Increasing Solubility: A Review Of Conventional And New Strategies. Asian Journal of Pharmaceutical Research and Development, 10(2), 144-153.

[5] Kumar, A. ., Dubey, A. ., & Singh, R. . (2022). Investigation on Anti-Ulcer Activity of Momordica dioica Fruits in Wistar Rat. International Journal for Research in Applied Sciences and Biotechnology, 9(1), 105–111. https://doi.org/10.31033/ijrasb.9.1.12

[6] AnubhavDubey, Deepanshi Tiwari,Yatendra Singh, Om Prakash, PankajSingh. Drug repurposing in Oncology: Opportunities and challenges. Int J of Allied Med Sci and Clin Res 2021; 9(1): 68-87.

[7] Dubey Anubhav, Tiwari Mamta, Kumar Vikas, Srivastava, Kshama, Singh, Akanksha. Investigation of Anti-Hyperlipidemic Activity of Vinpocetine in Wistar Rat international Journal of Pharmaceutical Research 2020; 12(02):1879-1882

[8] Akshay Tiwari, Shalini Singh, Anubhav Dubey and Yatendra Singh. "A preliminary study on anti-hyperlipidemic activity of cinnamon oil in wistar rat", 2021. International Journal of Current Research, 13, (03), 16741-16745.

[9] Dubey Anubhav, Tiwari M, Singh Yatendra, Kumar N, Srivastava K. Investigation of anti-Pyretic activity of vinpocetine in wistar rat, International Journal of Pharmaceutical Research 2020;12(2):1901-1906.

[10] Srivastava Kshama, Dubey Anubhav, Tiwari Mamta, Dubey Anurag, To evaluate the synergistic effect of pinitol with glimepride in diabetic wistar rats;7,(13)2020, 2058-2062.

[11] Dubey A., Kumar R., Kumar S., Kumar N., Mishra A., Singh Y. and Tiwari M. (2020). Review on Vinpocetine, Int. J. of Pharm. & Life Sci., 11(5): 6590-6597.

[12] Dubey, A., Yadav, P., Verma, P., & Kumar, R. (2022). Investigation of Proapoptotic Potential of Ipomoea carnea Leaf Extract on Breast Cancer Cell Line. Journal of Drug Delivery and Therapeutics, 12(1), 51-55.

[13] Kumar N., Dubey A., Mishra A. And Tiwari P. (2020). Ethosomes: A Novel Approach in Transdermal Drug Delivery System, Int. J. of Pharm. & Life Sci., 11(5): 6598-6608.

[14] Srivastava K., Tiwari M., Dubey A. and Dwivedi A. (2020). D-Pinitol - A Natural Phytomolecule and its Pharmacological effect, Int. J. of Pharm. & Life Sci., 11(5): 6609-6623.

[15] Sahana, S., Kumar, R., Nag, S., Paul, R., Chatterjee, I., & Guha, N. (2020). A REVIEW ON ALZHEIMER DISEASE AND FUTURE PROSPECTS.

[16] Kumar, R., & Dubey, A. PHYTOCHEMICAL INVESTICATION AND HEPTOPROTECTIVE EVALUTION ACACIA RUBICA EXTRACT ISONIZED AND PARACETAMOL INDUSED ANIMAL TOXICITY. *Turkish Journal of Physiotherapy and Rehabilitation*, *32*(3).

[17] Daharia, A., Jaiswal, V. K., Royal, K. P., Sharma, H., Joginath, A. K., Kumar, R., & Saha, P. (2022). A Comparative review on ginger and garlic with their pharmacological Action. *Asian Journal of Pharmaceutical Research and Development*, *10*(3), 65-69.

[18] Nyarko, R. O., Prakash, A., Kumar, N., Saha, P., & Kumar, R. (2021). Tuberculosis a globalized disease. *Asian Journal of Pharmaceutical Research and Development*, *9*(1), 198-201.

[19] Singh, M. K., Kumar, A., Kumar, R., Kumar, P. S., Selvakumar, P., & Chourasia, A. (2022). Effects of Repeated Deep Frying on Refractive Index and Peroxide Value of Selected Vegetable Oils. *International Journal for Research in Applied Sciences and Biotechnology*, *9*(3), 28-31.

[20] Nyarko, R. O., Kumar, R., Sharma, S., Chourasia, A., Roy, A., & Saha, P. (2022). ANTIBACTERIAL ACTIVITY OF HERBAL PLANT-TINOSPORA CORDIFOLIA AND CATHARNTHUS ROSEUS.

[21] Raj, A., Tyagi, S., Kumar, R., Dubey, A., & Hourasia, A. C. (2021). Effect of isoproterenol and thyroxine in herbal drug used as cardiac hypertrophy. *Journal of Cardiovascular Disease Research*, 204-217.

[22] PURABISAHA, R. K., RAWAT, S. S. N., & PRAKASH, A. (2021). A REVIEW ON NOVEL DRUG DELIVERY SYSTEM.

[23] Nyarko, R. O., Saha, P., Kumar, R., Kahwa, I., Boateng, E. A., Boateng, P. O., ... & Bertram, A. (2021). Role of Cytokines and Vaccines in Break through COVID 19 Infections. *Journal of Pharmaceutical Research International*, *33*, 2544-2549.

[24] KUMAR, R., SAHA, P., SARKAR, S., RAWAT, N., & PRAKASH, A. (2021). A REVIEW ON NOVEL DRUG DELIVERY SYSTEM. *IJRAR-International Journal of Research and Analytical Reviews (IJRAR)*, *8*(1), 183-199.

[25] Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A Review on Diabetes Mellitus: Type1 & Type2. *World Journal of Pharmacy and Pharmaceutical Sciences*, *9*(10), 838-850.

[26] Kumar, R., Saha, P., Pathak, P., Mukherjee, R., Kumar, A., & Arya, R. K. EVOLUTION OF TOLBUTAMIDE IN THE TREATMENT OF

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

DIABETES MELLITUS. *Jour. of Med. P'ceutical & Alli. Sci*, *9*.

[27] SHAFQAT ZAIDI, R. K. MEHRA, Dr. SACHIN TYAGI, ROSHAN KUMAR ANUBHAV DUBEY. (2021). Effect of Kalahari Cactus Extract on Appetitte, Body Weight And Lipid Profile In Cafeteria Diet Induced Obesity In Experimental Animal. *Annals of the Romanian Society for Cell Biology*, *25*(6), 13976-13987.

[28] Tiwari, A., Singh, S., Dubey, A., & Singh, Y. (2021). A preliminary study on antihyperlipidemic activity of cinnamon oil in wistar rat. *International Journal of Current Research*, *13*(03), 16741-16745.

[29] Kumar, N., Dubey, A., Mishra, A., & Tiwari, P. (2020). Ethosomes: A Novel Approach in Transdermal Drug Delivery System. *International Journal of Pharmacy & Life Sciences*, *11*(5).

[30] Dubey, A., Tiwari, D., Singh, Y., & Prakash, O. (2021). Pankaj Singh. Drug repurposing in Oncology: Opportunities and challenges. *Int J of Allied Med Sci and Clin Res*, *9*(1), 68-87.

[31] Vigen R, Weideman RA, Reilly RF. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol. 2011 Sep;43(3):813-9.

[32] Carroll MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003 May 01;67(9):1959-66.

[33] Loffing J. Paradoxical antidiuretic effect of thiazides in diabetes insipidus: another piece in the puzzle. J Am Soc Nephrol. 2004 Nov;15(11):2948-50.

[34] CRAWFORD JD, KENNEDY GC. Chlorothiazid in diabetes insipidus. Nature. 1959 Mar 28;183(4665):891-2.

[35] Burtscher M, Gatterer H, Faulhaber M, Burtscher J. Acetazolamide pre-treatment before ascending to high altitudes: when to start? Int J Clin Exp Med. 2014;7(11):4378-83.

[36] Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015 Mar;31(2):63-77

[37] Rosenbaum A, Winter M. Are diuretics effective for Ménière`s disease? Medwave. 2018 Mar 28;18(2):e7188.

[38] Tenny S, Patel R, Thorell W. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Mar 25, 2021. Mannitol

[39] Witherspoon B, Ashby NE. The Use of Mannitol and Hypertonic Saline Therapies in Patients with Elevated Intracranial Pressure: A Review of the Evidence. Nurs Clin North Am. 2017 Jun;52(2):249-260

[40] Ghannoum M, Gosselin S. Enhanced poison elimination in critical care. Adv Chronic Kidney Dis. 2013 Jan;20(1):94-101.

[41] Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT. Diuresis or urinary alkalinisation for salicylate poisoning? Br Med J (Clin Res Ed). 1982 Nov 13;285(6352):1383-6.

[42] Dubey Anubhav Ghosh Sekhar Niladry, Saxena Gyanendra Kumar, Purohit Debashis, Singh Shweta, (2022). Management implications for neurotoxic effects associated with antibiotic use. NeuroQuantology, 6(20), 304-328. doi: 10.14704/nq.2022.20.6.NQ22034.

[43] Dubey, A., Ghosh, N. S., Rathor, V. P. S., Patel, S., Patel, B., &Purohit, D. (2022). Sars- COV-2 infection leads to neurodegenerative or neuropsychiatric diseases. International Journal of Health Sciences, 6(S3), 2184–2197. https://doi.org/10.53730/ijhs.v6nS3.5980.

[44] Dubey A., Kumar R., Kumar S., Kumar N., Mishra A., Singh Y. and Tiwari M. (2020). Review on Vinpocetine, Int. J. of Pharm. & Life Sci., 11(5): 6590-6597.

[45] Srivastava K., Tiwari M., Dubey A. and Dwivedi A. (2020). D-Pinitol - A Natural Phytomolecule and its Pharmacological effect, Int. J. of Pharm. & Life Sci., 11(5): 6609-6623.

[46] Dubey, A., Tiwari, D., Singh, Y., & Prakash, O. (2021). Pankaj Singh. Drug repurposing in Oncology: Opportunities and challenges. *Int J of Allied Med Sci and Clin Res*, *9*(1), 68-87.

[47] Meher, C. P., Purohit, D., Kumar, A., Singh, R., & Dubey, A. (2022). An updated review on morpholine derivatives with their pharmacological actions. *International Journal of Health Sciences*, *6*(S3), 2218–2249. https://doi.org/10.53730/ijhs.v6nS3.5983.

[48] Patnaik, S., Purohit, D., Biswasroy, P., Diab, W. M., & Dubey, A. (2022). Recent advances for commedonal acne treatment by employing lipid nanocarriers topically. International Journal of Health Sciences, 6(S8), 180–205. https://doi.org/10.53730/ijhs.v6nS8.9671

[49] -Anubhav Dubey, Deepanshi Tiwari, Kshama Srivastava, Om Prakash and Rohit Kushwaha. A discussion on *vinca* plant. J Pharmacogn Phytochem 2020;9(5):27-31.

[50] kumar, R., Saha, P., Nyarko, R., Lokare, P., Boateng, A., Kahwa, I., Owusu Boateng, P., & Asum, C. (2022). Effect of Covid-19 in Management of Lung Cancer Disease: A Review. Asian Journal of Pharmaceutical Research and Development, 10(3), 58-64. https://doi.org/https://doi.org/10.22270/ajprd.v10i3.113.

[51] Rasheed Khushnuma, Gupta Dakshina , Dubey Anubhav, Singh Yatendra , A REVIEW ON β-ESCIN, Indian Journal of Medical Research and Pharmaceutical Sciences, 2021;8(1),10-16. DOI: https://doi.org/10.29121/ijmrps.v8.i1.2020.2.

[52] Dubey Anubhav, Kumar Abhay, Peeyush, Singh Jitendra, Medicinal property of Callistemon viminalis, International Journal of Pharmacognosy and Life Science 2021; 2(2): 15-20. DOI: https://doi.org/10.33545/27072827.2021.v2.i2a.35.

[53] Kumari Pushpa, Kumar Santosh, Shukla Bhanu Pratap, Dubey Anubhav, An overview on breast cancer,International Journal of Medical and all body

ISSN: 2583-4053

Volume-1 Issue-3 || August 2022 || PP. 11-20

https://doi.org/10.55544/jrasb.1.3.3

Health Research www.allmedicaljournal,2021;2(3),59-65.www.allmedicaljournal.com.

[54] Yadav Priyanka, Dubey Anubhav, Formulation and characterization of anti-epileptic drug transdermal patch for enhance skin permeation, European Journal of Biomedical and Pharmaceutical Sciences 2021: 8, (9), 784-790. http://www.ejbps.com.

[55] Prerna, Dubey Anubhav, Gupta Ratan, Nanoparticles: An Overview, Drugs and Cell Therapies in Haematology2021;10(1),1487-1497.

[56] Rajeshwari Shweta Raj, Shukla Dr. Prashant, Dubey Anubhav, Delivery of repurposed drugs for cancer: opportunities and challenges,European Journal of Pharmaceutical and Medical Research 2021,8(9), 271-281. www.ejpmr.com.

[57] Saha Purabi Dubey Anubhav, Kumar Dr. Sanjay, Kumar Roshan, Evaluation of Enzyme Producing K. Pneumoniae and Their Susceptibility to Other Anti-Biotics, International Journal of Innovative Science and Research Technology 2022; 7(5), 351-353. www.ijisrt.com.

[58] Panda Braja Bihari, Patnaas, Swastik, Purohit Debashish, Das Shubhashree, Dubey Anubhav, Impact of sodium starch glycolate on Physico-chemical characteristics of mouth dissolving film of Fexofenadine, Neuro Quantology2022; 20(6) 7604-7613. doi: 10.14704/nq.2022.20.6.NQ22759.